Patents Examined by Noble E Jarrell
  • Patent number: 11225504
    Abstract: The present invention discloses a functional polypeptide which is 1) a polypeptide having the amino acid sequence of SEQ ID No. 1; or 2) a polypeptide having a substitution or deletion or addition of one or several amino acids from the sequence shown in SEQ ID No. 1 that has the same or similar function. The invention also discloses the utility of the described functional polypeptide. The functional polypeptide of the present invention can significantly inhibit bleomycin-induced pulmonary fibrosis formation and has a remarkable effect of preventing and treating pulmonary fibrosis.
    Type: Grant
    Filed: June 16, 2018
    Date of Patent: January 18, 2022
    Inventors: Haitao Zhang, Huajun Yu, Jun Wu, Hui Luo
  • Patent number: 11220493
    Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections.
    Type: Grant
    Filed: October 8, 2020
    Date of Patent: January 11, 2022
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 11208396
    Abstract: This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: Giles Albert Brown, Benjamin Gerald Tehan
  • Patent number: 11208413
    Abstract: The present invention relates to a compound that is useful as an inhibitor of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising this compound and to methods of using this compound in the treatment of cancer and methods of treating cancer.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: December 28, 2021
    Assignee: ALMAG DISCOVERY LIMITED
    Inventors: Peter Hewitt, Frank Burkamp, Andrew Wilkinson, Hugues Miel, Colin O'Dowd
  • Patent number: 11207420
    Abstract: Provided is a method for modifying a chimeric antigen receptor-modified T cell (CAR-T cell). The method comprises expressing an SCFV-CDS TM-4-1BB-CD3? molecule in a T cell. The CAR-T cell prepared using the method can specifically recognize and bind to a tumor cell with elevated expression of a ROBO1 protein, and can be used to prevent and treat a corresponding tumor-related disease.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: December 28, 2021
    Assignee: SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
    Inventors: Jiaqiang Cai, Tongtong Xue, Shuai Song, Jing Wang, Qiang Tian, Liang Xiao, Hanwen Deng, Liping Liu, Zujian Tang, Hong Zeng, Rongrong Long, Hongmei Song, Qiang Zhang, Guoqing Zhong, Dengnian Liu, Haitao Huang, Ruibin Hu, Lichun Wang, Jingyi Wang
  • Patent number: 11203602
    Abstract: The present invention provides a novel macrocyclic prodrug compound of general Formula (I), a pharmaceutical composition comprising a compound of Formula (I), and a method for treating diseases mediated by HDAC enzymes by administering a compound of Formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, A and Z are defined herein.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: December 21, 2021
    Assignee: OnKure, Inc.
    Inventor: Anthony D. Piscopio
  • Patent number: 11203601
    Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: December 21, 2021
    Assignees: The Broad Institute, Inc., Biogen MA Inc.
    Inventors: Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen
  • Patent number: 11192890
    Abstract: Fibroblast Growth Factor Receptor kinase inhibitors and prodrugs thereof of Formula (I) and their use for the treatment of hyper-proliferative diseases such as retinopathy, psoriasis, rheumatoid arthritis, osteoarthritis, septic arthritis, tumour metastasis, periodontal disease, corral ulceration, proteinuria, coronary thrombosis from atherosclerotic plaque, aneurismal aorta, dystrophobic epidermolysis bullosa, degenerative cartilage loss following traumatic joint injury, osteopenias mediated by MMP activity, tempero mandibular joint disease, and demyelating disease of the nervous system.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: December 7, 2021
    Assignees: AUCKLAND UNISERVICES LIMITED, GUANGZHOU INSTITUTE OF BIOMEDICINE AND HEALTH
    Inventors: Adam Vorn Patterson, Jeffrey Bruce Smaill, Amir Ashoorzadeh, Christopher Paul Guise, Christopher John Squire, Swarnalatha Akuratiya Gamage, Maria Rosaria Abbattista, Matthew Roy Bull, Angus Cheverton Grey, Xueqiang Li, Ke Ding, Xiaomei Ren, Shuang Jiang, Zhengchao Tu
  • Patent number: 11191732
    Abstract: Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into “soluble” colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: December 7, 2021
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Barbara S. Slusher, Anne Le, Takashi Tsukamoto
  • Patent number: 11186546
    Abstract: The present invention discloses a method for preparing 2,3-dichloro-5-trifluoromethylpyridine, comprising at a temperature of 100˜150° C. and a pressure of 0.5˜5.0 MP, in presence of at least one catalyst selected from supported metal chloride, supported zeolite molecular sieve and supported heteropolyacid, 2-chloro-5-trifluoromethylpyridine reacts with chlorine gas to obtain 2,3-dichloro-5-trifluoromethylpyridine. The preparing method provided by the present invention has advantages such as high selectivity of desired product, high utilization rate of chlorine gas, moderate process condition, simple operation and less three wastes. The present invention also discloses a preparing method for preparing 2-chloro-5-trifluoromethylpyridine, which is capable of reducing unit consumption, reducing separation cost, and improving safety compared to the prior art.
    Type: Grant
    Filed: December 5, 2018
    Date of Patent: November 30, 2021
    Assignees: Zhejiang Lantian Environmental Protection Hi-Tech Co., Ltd., Zhejiang Research Institute of Chemical Industry Co., Ltd., Sinochem Lantian Co., Ltd.
    Inventors: Wanjin Yu, Shengda Lin, Minyang Liu, Wucan Liu, Jianjun Zhang, Xianjin Chen
  • Patent number: 11174240
    Abstract: The present invention relates to a novel crystalline 3-phenyl-4-propyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol hydrochloride, a method for preparing the compound, and a pharmaceutical composition containing the compound as an active ingredient.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 16, 2021
    Assignee: Aptabio Therapeutics Inc.
    Inventors: Sung Hwan Moon, Soo Jin Lee, Sung Chan Lee
  • Patent number: 11174243
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: November 16, 2021
    Assignees: Sunesis Pharmaceuticals, Inc., Biogen MA Inc.
    Inventors: J. Michael Macphee, Linda L. Neuman
  • Patent number: 11155554
    Abstract: Provided herein are rigid macrocycles comprising a first redox-active subunit and a second redox-active subunit, wherein the first redox-active unit and the second redox-active unit are different subunits. Also provided herein are methods of preparation of the rigid macrocycles and use thereof, for example, in the first of energy generation and storage.
    Type: Grant
    Filed: March 16, 2017
    Date of Patent: October 26, 2021
    Assignees: Northwestern University, KING ABDULAZIZ CITY FOR SCIENCE AND TECHNOLOGY (KACST)
    Inventors: James Fraser Stoddart, Siva Krishna Mohan Nalluri, Zhichang Liu
  • Patent number: 11142512
    Abstract: The present invention relates to nebivolol synthesis method and intermediate compound thereof. Specifically, the present invention relates to a method for synthesizing nebivolol, intermediate compound thereof, and a method for preparing the intermediate compound.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: October 12, 2021
    Assignee: ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
    Inventor: Zhiguo Zheng
  • Patent number: 11136327
    Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: October 5, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: James R. Corte, Tianan Fang, Carl P. Decicco, Donald J. P. Pinto, Karen A. Rossi, Zilun Hu, Yoon Jeon, Mimi L. Quan, Joanne M. Smallheer, Yufeng Wang, Wu Yang
  • Patent number: 11135308
    Abstract: The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: October 5, 2021
    Assignee: IMMUNOGEN, INC.
    Inventor: Wayne C. Widdison
  • Patent number: 11135227
    Abstract: The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: October 5, 2021
    Assignee: CTI BIOPHARMA CORP.
    Inventors: Stephanie Blanchard, Cheng Hsia Angelina Lee, Harish Kumar Mysore Nagaraj, Anders Poulsen, Eric T. Sun, Yee Ling Evelyn Tan, Anthony Deodaunia William
  • Patent number: 11124491
    Abstract: A process for the manufacture of vortioxetine HBr ?-form is provided.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: September 21, 2021
    Assignee: H. Lundbeck A/S
    Inventor: Hans Petersen
  • Patent number: 11117892
    Abstract: The present invention relates to a pyrrolo-pyridine derivative compound, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for the prevention or treatment of protein kinase-related diseases. A compound represented by chemical formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, according to the present invention, has excellent inhibitory activity against various protein kinases including DYRK1A, and therefore, the pharmaceutical composition containing the same as an active ingredient can be favorably used in the treatment or prevention of protein kinase-related diseases. Particularly, the pharmaceutical composition can be effectively used in the prevention, treatment, or alleviation of Alzheimer's disease, dementia, or Alzheimer's dementia.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: September 14, 2021
    Inventors: Hwan Geun Choi, Eunhwa Ko, Joong-heui Cho, Jung Beom Son, Yi Kyung Ko, Jin-Hee Park, So Young Kim, Seock Yong Kang, Seungyeon Lee, Hee Yoon Ryu, Nam Doo Kim, Sang Bum Kim, Sun-Hwa Lee, Dayea Kim, Sun Joo Lee, Sungchan Cho, Kyu-Sun Lee, Kweon Yu, Miri Choi, Ja Wook Koo, Hyang-Sook Hoe
  • Patent number: 11116847
    Abstract: The present invention provides Ligand-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 14, 2021
    Assignee: Seagen Inc.
    Inventors: Robert Kolakowski, Scott Jeffrey, Patrick Burke